Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity

Protein Expression and Purification

Volumn 61, Issue 1, 2008, Pages 22-30

  Nguyen, Thi H O ^a,b   Mifsud, Nicole A ^b   Stewart, Lisbeth A ^a   Rose, Mingus J ^a   Etto, Tamara L ^a   Williamson, Nicholas A ^c   Purcell, Anthony W ^c   Kotsimbos, Tom ^a,b   Schwarer, Anthony P ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

HCMV; IE1 pp65; Protein purification

Indexed keywords

EPITOPE; IE1 PP65 RECOMBINANT PROTEIN, HUMAN CYTOMEGALOVIRUS; IE1-PP65 RECOMBINANT PROTEIN, HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY PROTEIN; MATRIX PROTEIN; PHOSPHOPROTEIN; PRIMER DNA; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARMYWORM; ARTICLE; BACULOVIRUS; CD8+ T LYMPHOCYTE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANIMALS; BACULOVIRIDAE; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNODOMINANT EPITOPES; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SPODOPTERA; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 47749087022     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.05.001     Document Type: Article

References (32)

1. Sinclair J. Cellular sites and mechanisms of human cytomegalovirus latency. In: Cann A.J. (Ed). DNA Virus Replication (2000), Oxford University Press, New York 156-172
2. Reusser P., Riddell S.R., Meyers J.D., and Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 (1991) 1373-1380
3. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98 (2001) 1358-1364
4. Einsele H., Hebart H., Bokemeyer C., Kanz L., Jahn G., and Muller C.A. Cytomegalovirus infection following haematopoietic stem cell transplantation. In: Scholz M., Rabenau H.F., Doerr H.W., and Cinatl J. (Eds). CMV-Related Immunopathology. Monographs in Virology (1998), Karger, Basel 106-118
5. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A., Brenner M.K., and Heslop H.E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
6. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S.R., Rafter L., Clarke E., Slaughter R., Falk M.C., Douglas J., Williams T., Elliott S.L., and Moss D.J. Activation adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative diseases. Proc. Natl. Acad. Sci. USA 96 (1999) 10391-10396
7. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044
8. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., and Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362 (2003) 1375-1377
9. Perruccio K., Tosti A., Burchielli E., Topini F., Ruggeri L., Carotti A., Capanni M., Urbani E., Mancusi A., Aversa F., Martelli M.F., Romani L., and Velardi A. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106 (2005) 4397-4406
10. Peggs K., Verfuerth S., and Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 97 (2001) 994-1000
11. Bissinger A.L., Rauser G., Hebart H., Frank F., Jahn G., and Einsele H. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp. Hematol. 30 (2002) 1178-1184
12. Einsele H., Rauser G., Grigoleit U., Hebart H., Sinzger C., Riegler S., and Jahn G. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy 4 (2002) 49-54
13. Micklethwaite K., Hansen A., Foster A., Snape E., Antonenas V., Sartor M., Shaw P., Bradstock K., and Gottlieb D. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 13 (2007) 707-714
14. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., Proesch S., Reinke P., Volk H.D., Lehmkuhl H., and Kern F. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201 (2005) 1031-1036
15. Trivedi D., Williams R.Y., O'Reilly R.J., and Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 105 (2005) 2793-2801
16. Vaz-Santiago J., Lule J., Rohrlich P., Jacquier C., Gibert N., Le Roy E., Betbeder D., Davignon J.L., and Davrinche C. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J. Virol. 75 (2001) 7840-7847
17. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., Pruss A., Gratama J.W., Volkmer-Engert R., Ewert R., Reinke P., Volk H.D., and Picker L.J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185 (2002) 1709-1716
18. Le Roy E., Baron M., Faigle W., Clement D., Lewinsohn D.M., Streblow D.N., Nelson J.A., Amigorena S., and Davignon J.L. Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4(+) T lymphocytes. J. Immunol. 169 (2002) 1293-1301
19. Chenchik A., Diachenko L., Moqadam F., Tarabykin V., Lukyanov S., and Siebert P.D. Full-length cDNA cloning and determination of mRNA 5′ and 3′ ends by amplification of adaptor-ligated cDNA. Biotechniques 21 (1996) 526-534
20. Schnurr M., Chen Q., Shin A., Chen W., Toy T., Jenderek C., Green S., Miloradovic L., Drane D., Davis I.D., Villadangos J., Shortman K., Maraskovsky E., and Cebon J. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105 (2005) 2465-2472
21. Arrode G., Boccaccio C., Lule J., Allart S., Moinard N., Abastado J.P., Alam A., and Davrinche C. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J. Virol. 74 (2000) 10018-10024
22. Arrode G., and Davrinche C. Dendritic cells and HCMV cross-presentation. Curr. Top. Microbiol. Immunol. 276 (2003) 277-294
23. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., and Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199 (2004) 9-26
24. + T cell clone. Eur. J. Immunol. 26 (1996) 1110-1117
25. +T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77 (2003) 5226-5240
26. Kern F., Surel I.P., Faulhaber N., Frommel C., Schneider-Mergener J., Schonemann C., Reinke P., and Volk H.D. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73 (1999) 8179-8184
27. Solache A., Morgan C.L., Dodi A.I., Morte C., Scott I., Baboonian C., Zal B., Goldman J., Grundy J.E., and Madrigal J.A. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J. Immunol. 163 (1999) 5512-5518
28. Retiere C., Prod'homme V., Imbert-Marcille B.M., Bonneville M., Vie H., and Hallet M.M. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J. Virol. 74 (2000) 3948-3952
29. Kuzushima K., Hayashi N., Kimura H., and Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98 (2001) 1872-1881
30. Chen F.E., Aubert G., Travers P., Dodi I.A., and Madrigal J.A. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 4 (2002) 41-48
31. Frankenberg N., Pepperl-Klindworth S., Meyer R.G., and Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295 (2002) 208-216
32. Kondo E., Akatsuka Y., Kuzushima K., Tsujimura K., Asakura S., Tajima K., Kagami Y., Kodera Y., Tanimoto M., Morishima Y., and Takahashi T. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 103 (2004) 630-638